semaglutide depression anxiety bipolar semaglutide The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy Penn study focuses on semaglutide – Depression and anxiety update for

Grafted fat survival is approximately 50 to 70 percent

And most study participants stopped taking their GLP-1 agonist once they found out they were pregnant

Compounding rules tightened in 2026 Both drugs are off the FDA shortage list, so large-scale compounding is no longer broadly allowed it's now mostly limited to patients with a documented medical need, like an ingredient allergy or a non-standard dose

But notably those with obesity had a slightly lower prevalence rate ratio, so maybe less alcohol use as compared to those without obesity. There are some limitations of the analysis, she acknowledged, pointing to the cross-sectional design and the possibility of unmeasured confounding